Allogeneic sem cell transplantatin for hematologic malignancies in HIV+ patients – pro
Mullanoviche had good results with alloHSCT without transplant-related mortality or major infectious complications. Their HIV viral load remained undetectable without the use of protease inhibitors or need to discontinue antiretroviral therapy. His paper supported considering selected HIV-infected patients for alloHSCT when indicated for the management of their hematologic malignancies. Hutter reviewed 25 years of experience in transplanting HIV patients and concluded that patients with HIV infection should be offered allogeneic HSCT if there is an indication to treat a hematological disease.
NCCN AML AML-4 2021
Mulanovich VE, Desai PA, Popat UR. Allogeneic stem cell transplantation for HIV-positive patients with hematologic malignancies. AIDS. 2016;30(17):2653-2657. doi:10.1097/QAD.0000000000001240
Hütter G, Zaia JA. Allogeneic hematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol. 2011;163(3):284-295. doi:10.1111/j.1365-2249.2010.04312.x